Recent studies have explored molecular determinants of immunotherapy response: for example, LAMTOR1 was shown to inhibit PD-L1 exosomal secretion, thereby enhancing anti-tumor immunity(Wu et al. 2024).while metabolic reprogramming was linked to immune checkpoint inhibitor (ICI) efficacy(Zheng et al. 2024). Here, LAMTOR1 is linked to neoplasm.